Bringing Medicines for HIV Prevention to a Family Planning Clinic
HIV · PrEP
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Interventional
- Phase
- Not applicable
- Age range
- 16 years - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Accepted
- Participants
- 83 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
The goal of this clinical trial is to understand what patients and physicians think about providing medications to prevent HIV transmission to patients in a family planning clinic. These medications are known as pre-exposure prophylaxis, or PrEP. The main questions to answer are:
1. Do patients find it acceptable to be asked about, and offered, PrEP during their visit to a family planning clinic?
2. What things make it easier or harder to ask about PrEP in a family planning clinic setting?
3. What things make it easier or harder to begin PrEP in a family planning clinic setting?
Patient participants:
1. Will receive standardized counseling about PrEP.
2. Will have the opportunity to begin PrEP as part of their routine, ongoing care.
3. Will be asked to complete a survey about their experiences.
Physician participants:
1. Will receive standardized education about PrEP.
2. Will talk to patient participants about PrEP, and support patient participants who want to begin PrEP.
3. Will be asked to complete pre-and post-study surveys about their experiences.
4. May be asked to complete a post-study in-depth interview about their experiences.
Read the full description
In the proposed pilot study, the investigators' goal is to improve community health resources available to Rhode Islanders to lower their risk of HIV acquisition, via the following specific aims:
1. Evaluate the patient acceptability of HIV pre-exposure prophylaxis (PrEP) eligibility screening and initiation in an ob/gyn-staffed family planning clinic.
2. Assess the barriers, facilitators, and feasibility of PrEP eligibility screening in an ob/gyn-staffed family planning clinic.
3. Assess the barriers, facilitators, and feasibility of delivery and uptake of PrEP in an ob/gyn-staffed family planning clinic.
Overall, the investigators' expected outcome is to have exploratory data to inform a scalable intervention to implement PrEP access, which can be deployed in family planning clinic settings, and which is designed in accordance with acceptability and feasibility data from patients and providers. Since the existing data suggest that ob/gyn-staffed family planning clinics are an ideal site both as a catchment area for patients who are at higher risk for HIV acquisition, and in terms of technical capacity and provider skill set, the next step to expand PrEP service delivery in these settings is to assess the barriers and facilitators to such care, in order to meet patients where they are, with the care they need. The goal is to situate the protocol to fit into the usual clinical workflow of a busy family planning clinic.
The investigators will develop and implement a standardized PrEP eligibility screening instrument and initiation protocol, based on CDC guidelines. The investigators will survey patient and physician participants about feasibility and acceptability of study procedures. Patient participants will be approached by a research assistant, who will inform eligible individuals about the purpose, risks, and benefits of the study. The research assistant will obtain informed consent from participants. Physicians will then screen participants for PrEP eligibility per protocol, and will offer initiation of PrEP. These medications are not investigational, are part of standard of care STI prevention, and are not themselves the primary subject of this study.
The investigators' primary data collection will be via survey. Patient participants will receive a $25 gift card for completing the post-intervention survey. Physician participants will receive pre- and post-study surveys, and a subgroup will participate in focused interviews.
There is no control arm in this study. The alternative to participation in this study is to simply undergo (or provide) routine care in the investigators' Family Planning Clinic, which does not currently include PrEP provision - though, as described above, such care is within the scope of routine care in ob/gyn settings.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
This study will include patient participants who:
- Are age 16 or older
- Are presenting for care at the Women and Infants Hospital of Rhode Island Family Planning Clinic
- Speak English or Spanish
- Have decisional capacity
This study will exclude patient participants who:
\- Are currently seeking abortion care
This study will include physician participants who:
\- Provide care at the Women and Infants Hospital of Rhode Island Family Planning Clinic
This study will not have any specific exclusion criteria for physician participants.
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not randomized
- Masking
- No masking
Patient Participant
Not reported in this registry record.
Behavioral: Patient participant screening
Physician Participant
Not reported in this registry record.
Behavioral: Physician participant training
Patient participant screening BEHAVIORAL
Patient participants will be provided with the standardized PrEP screening and initiation protocol.
Physician participant training BEHAVIORAL
Physician participants will be trained in the investigators' standardized PrEP screening and initiation protocol.
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Acceptability of Intervention Measure
Time frame: Up to hour 6 for patient participants; Up to month 12 for physician participants
A validated measure of acceptability, administered via questionnaire. 4 Likert scale items. Item score range 1-5. Higher scores reflect higher acceptability.
Feasibility of Intervention Measure
Time frame: Up to hour 6 for patient participants; Up to month 12 for physician participants
A validated measure of feasibility, administered via questionnaire. 7-12 Likert scale items. Item score range 1-5. Higher scores reflect higher feasibility.
Intervention Appropriateness Measure
Time frame: Up to hour 6 for patient participants; Up to month 12 for physician participants
A validated measure of appropriateness, administered via questionnaire. 4 Likert scale items. Item score range 1-5. Higher scores reflect higher appropriateness.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Women and Infants Hospital of Rhode IslandProvidence, Rhode Island, United StatesRecruiting
Study team and timeline
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Study start
- May 28, 2026 Actual
- Primary completion
- Dec 15, 2026 Estimated
- Study completion
- Dec 31, 2026 Estimated
- First posted
- Apr 16, 2025 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Implementing HIV Pre-Exposure Prophylaxis in a Family Planning Clinic: A Study of Feasibility and Acceptability (Aka The Pilot Fish Study)
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026